BEYOND BLOOD SUGAR CONTROL: A COMPREHENSIVE REVIEW OF DPP-4 INHIBITORS AND THEIR EXPANDING LANDSCAPE
Main Article Content
Keywords
Type 2 diabetes, DPP-4 inhibitors, GLP-1, GIP, insulin resistance, beta cell function, hypoglycemia, safety, long-term effects, immune function, COVID-19
Abstract
Type 2 diabetes, a prevalent chronic condition marked by insulin resistance and impaired beta cell function, presents a significant healthcare challenge. This review examines the potential of DPP-4 inhibitors, a novel class of medications, in managing this condition. DPP-4 inhibitors function by blocking the dipeptidyl peptidase-4 (DPP-4) enzyme, leading to increased levels of the incretin hormones GLP-1 and GIP. These hormones stimulate insulin release and suppress glucagon production, ultimately lowering blood sugar. Their safety, tolerability, and low risk of hypoglycaemia make them an attractive treatment option. Currently, DPP-4 inhibitors are increasingly becoming first-line therapy, demonstrating efficacy in controlling blood sugar. However, long-term safety and their potential influence on immune function and susceptibility to COVID-19 require further investigation.
This review delves into the latest research on DPP-4 inhibitors, exploring their mechanisms of action, clinical effectiveness, and safety profile. Additionally, it highlights areas for future research, considering long-term effects, potential risks, and emerging questions related to immune function and COVID-19. By offering a comprehensive overview of DPP-4 inhibitors, this review aims to inform healthcare professionals and researchers about their potential in managing type 2 diabetes and pave the way for future advancements in diabetes care.
References
1. Flatt AJS, Greenbaum CJ, Shaw JAM, Rickels MR. Pancreatic islet reserve in type 1 diabetes. Annals of the New York Academy of Sciences. 2021;1495(1):40–54.
2. Andersen DB, Holst JJ. Peptides in the regulation of glucagon secretion. Peptides. 2022;148:170683.
3. Padhi S, Nayak AK, Behera A. Type II diabetes mellitus: a review on recent drug based therapeutics. Biomedicine & Pharmacotherapy. 2020;131:110708.
4. Deacon CF. Peptide degradation and the role of DPP-4 inhibitors in the treatment of type 2 diabetes. Peptides. 2018;100:150–7.
5. Deacon CF. Metabolism of GIP and the contribution of GIP to the glucose-lowering properties of DPP-4 inhibitors. Peptides. 2020;125:170196.
6. Enz N, Vliegen G, De Meester I, Jungraithmayr W. CD26/DPP4-a potential biomarker and target for cancer therapy. Pharmacology & therapeutics. 2019;198:135–59.
7. Kalaiselvi P. Compare the Safety and Efficacy of Glimepiride–Metformin with Vildagliptin-Metformin in Type 2 Diabetes Mellitus Patients in a Tertiary Care Hospital. Karpaga Vinayaga Institute of Medical Sciences, Madhuranthagam; 2016.
8. Berg M. Design and Synthesis of Novel Drug Candidates for the Treatment of Type 2 Diabetes and Insulin Resistance: Potential SHIP2 Inhibitors. 2021;
9. Mahtani K, MMath BPBs, Wang MAB, Barron A. Activation of GLP-1 receptor signalling by sacubitril/valsartan: Implications for patients with poor glycaemic control. International Journal of Cardiology. 2022;
10. Kumar S, Mittal A, Mittal A. A review upon medicinal perspective and designing rationale of DPP-4 inhibitors. Bioorganic & Medicinal Chemistry. 2021;46:116354.
11. Ghate M, V Jain S. Fragment based HQSAR modeling and docking analysis of conformationally rigid 3-azabicyclo [3.1. 0] hexane derivatives to design selective DPP-4 inhibitors. Letters in Drug Design & Discovery. 2014;11(2):184–98.
12. Adelusi TI, Du L, Chowdhury A, Xiaoke G, Lu Q, Yin X. Signaling pathways and proteins targeted by antidiabetic chalcones. Life Sciences. 2021;284:118982.
13. Diaz DB. Identification of Novel Structural Motifs for Mining the Conformational Space of Boron-and Peptide-based Molecules. University of Toronto (Canada); 2020.
14. Sečník J. Diabetes Mellitus in Patients with Dementia: Clinical Care and Pharmacological Treatment. Karolinska Institutet (Sweden); 2021.
15. Deacon CF. Physiology and pharmacology of DPP-4 in glucose homeostasis and the treatment of type 2 diabetes. Frontiers in endocrinology. 2019;10:80.
16. Tura A, Göbl C, Vardarli I, Pacini G, Nauck M. Insulin clearance and incretin hormones following oral and “isoglycemic” intravenous glucose in type 2 diabetes patients under different antidiabetic treatments. Scientific Reports. 2022;12(1):1–10.
17. Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes, Obesity and Metabolism. 2018;20:5–21.
18. Holst JJ. The incretin system in healthy humans: The role of GIP and GLP-1. Metabolism. 2019;96:46–55.
19. Gasbjerg LS, Bergmann NC, Stensen S, Christensen MB, Rosenkilde MM, Holst JJ, et al. Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists. Peptides. 2020;125:170183.
20. Moffett RC, Naughton V. Emerging role of GIP and related gut hormones in fertility and PCOS. Peptides. 2020;125:170233.
21. Pfeiffer AFH, Keyhani-Nejad F. High glycemic index metabolic damage–a pivotal role of GIP and GLP-1. Trends in Endocrinology & Metabolism. 2018;29(5):289–99.
22. Modvig IM, Kuhre RE, Jepsen SL, Xu SFS, Engelstoft MS, Egerod KL, et al. Amino acids differ in their capacity to stimulate GLP-1 release from the perfused rat small intestine and stimulate secretion by different sensing mechanisms. American Journal of Physiology-Endocrinology and Metabolism. 2021;320(5):E874–85.
23. Mathiesen DS, Bagger JI, Bergmann NC, Lund A, Christensen MB, Vilsbøll T, et al. The effects of dual GLP-1/GIP receptor agonism on glucagon secretion—a review. International journal of molecular sciences. 2019;20(17):4092.
24. Kapodistria K, Tsilibary E, Kotsopoulou E, Moustardas P, Kitsiou P. Liraglutide, a human glucagon‐like peptide‐1 analogue, stimulates AKT‐dependent survival signalling and inhibits pancreatic β‐cell apoptosis. Journal of Cellular and Molecular Medicine. 2018;22(6):2970–80.
25. Hwang H-J, Yang YR, Kim HY, Choi Y, Park K-S, Lee H, et al. Phospholipase C‐β1 potentiates glucose‐stimulated insulin secretion. The FASEB Journal. 2019;33(10):10668–79.
26. Fisman EZ, Tenenbaum A. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: A novel cardiometabolic therapeutic prospect. Cardiovascular Diabetology. 2021;20(1):1–5.
27. Ahren B. DPP-4 inhibitors. Best Practice & Research Clinical Endocrinology & Metabolism. 2007;21(4):517–33.
28. Nauck MA, Wefers J, Meier JJ. Treatment of type 2 diabetes: challenges, hopes, and anticipated successes. The Lancet Diabetes & Endocrinology. 2021;9(8):525–44.
29. Holst JJ. From the incretin concept and the discovery of GLP-1 to today’s diabetes therapy. Frontiers in Endocrinology. 2019;10:260.
30. Samms RJ, Coghlan MP, Sloop KW. How may GIP enhance the therapeutic efficacy of GLP-1? Trends in Endocrinology & Metabolism. 2020;31(6):410–21.
31. Gribble FM, Reimann F. Metabolic messengers: Glucagon-like peptide 1. Nature Metabolism. 2021;3(2):142–8.
32. Codevilla F, Santana E, López AM, Gaidon A. Exploring the limitations of behavior cloning for autonomous driving. In: Proceedings of the IEEE/CVF International Conference on Computer Vision. 2019. p. 9329–38.
33. Tschöp M, Nogueiras R, Ahrén B. Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy. Diabetologia. 2023;1–13.
34. Alsalim W, Persson M, Ahrén B. Different glucagon effects during DPP‐4 inhibition versus SGLT‐2 inhibition in metformin‐treated type 2 diabetes patients. Diabetes, Obesity and Metabolism. 2018;20(7):1652–8.
35. Sebastián-Martín A, Sánchez BG, Mora-Rodríguez JM, Bort A, Díaz-Laviada I. Role of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology. Biomedicines. 2022;10(8):2026.
36. Boer GA, Holst JJ. Incretin hormones and type 2 diabetes—mechanistic insights and therapeutic approaches. Biology. 2020;9(12):473.
37. Sharma A, Virmani T, Sharma A, Chhabra V, Kumar G, Pathak K, et al. Potential Effect of DPP-4 Inhibitors Towards Hepatic Diseases and Associated Glucose Intolerance. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2022;1845–64.
38. Abbatecola AM, Morley JE. Endocrine and Metabolic Changes with Aging. Endocrine and Metabolic Medical Emergencies: A Clinician’s Guide. 2018;182.
39. Holst JJ. Glucagon and other proglucagon-derived peptides in the pathogenesis of obesity. Frontiers in Nutrition. 2022;9.
40. Packer M. Do DPP-4 inhibitors cause heart failure events by promoting adrenergically mediated cardiotoxicity? Clues from laboratory models and clinical trials. Circulation research. 2018;122(7):928–32.
41. Kim H-R, Tagirasa R, Yoo E. Covalent small molecule immunomodulators targeting the protease active site. Journal of Medicinal Chemistry. 2021;64(9):5291–322.
42. Andersen B. DOCTORAL DISSERTATION Translational Aspects of FGF21. 2019;
43. Subrahmanyan NA, Koshy RM, Jacob K, Pappachan JM. Efficacy and cardiovascular safety of DPP-4 inhibitors. Current Drug Safety. 2021;16(2):154–64.
44. Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nature Reviews Endocrinology. 2020;16(11):642–53.
45. Proença C, Ribeiro D, Freitas M, Carvalho F, Fernandes E. A comprehensive review on the antidiabetic activity of flavonoids targeting PTP1B and DPP-4: a structure-activity relationship analysis. Critical reviews in food science and nutrition. 2022;62(15):4095–151.
46. Milluzzo RP, Franchina GA, Capodanno D, Angiolillo DJ. Selatogrel, a novel P2Y12 inhibitor: a review of the pharmacology and clinical development. Expert Opinion on Investigational Drugs. 2020;29(6):537–46.
47. Wu J, Chen Y, Shi X, Gu W. Dipeptidyl peptidase IV (DPP IV): a novel emerging target for the treatment of type 2 diabetes. Journal of Nanjing Medical University. 2009;23(4):228–35.
48. Saini K, Sharma S, Khan Y. DPP-4 inhibitors for treating T2DM-hype or hope? an analysis based on the current literature. Frontiers in Molecular Biosciences. 2023;10.
49. Mikov M, Pavlović N, Stanimirov B, Đanić M, Goločorbin-Kon S, Stankov K, et al. DPP-4 inhibitors: renoprotective potential and pharmacokinetics in type 2 diabetes mellitus patients with renal impairment. European journal of drug metabolism and pharmacokinetics. 2020;45(1):1–14.
50. Iwaniak A, Darewicz M, Minkiewicz P. Peptides derived from foods as supportive diet components in the prevention of metabolic syndrome. Comprehensive Reviews in Food Science and Food Safety. 2018;17(1):63–81.
51. McLean BA, Wong CK, Campbell JE, Hodson DJ, Trapp S, Drucker DJ. Revisiting the complexity of GLP-1 action from sites of synthesis to receptor activation. Endocrine reviews. 2021;42(2):101–32.
52. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes–state-of-the-art. Molecular metabolism. 2021;46:101102.
53. Levi M. Pathogenesis and diagnosis of disseminated intravascular coagulation. International journal of laboratory hematology. 2018;40:15–20.
54. AlRasheid N. Effect of different surgical weight-loss interventions and ethnicity on GLP-1 secretion. UCL (University College London); 2018.
55. Bianchini G, Nigro C, Sirico A, Novelli R, Prevenzano I, Miele C, et al. A new synthetic dual agonist of GPR120/GPR40 induces GLP-1 secretion and improves glucose homeostasis in mice. Biomedicine & Pharmacotherapy. 2021;139:111613.
56. Ren Z-L, Li C-X, Ma C-Y, Chen D, Chen J-H, Xu W-X, et al. Linking Nonalcoholic Fatty Liver Disease and Brain Disease: Focusing on Bile Acid Signaling. International Journal of Molecular Sciences. 2022;23(21):13045.
57. Masi EB, Valdés-Ferrer SI, Steinberg BE. The vagus neurometabolic interface and clinical disease. International journal of obesity. 2018;42(6):1101–11.
58. Hoffman S, Alvares D, Adeli K. GLP-1 attenuates intestinal fat absorption and chylomicron production via vagal afferent nerves originating in the portal vein. Molecular Metabolism. 2022;65:101590.
59. Lim S, Bae JH, Kwon H-S, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nature Reviews Endocrinology. 2021;17(1):11–30.
60. Zhang T, Perkins MH, Chang H, Han W, de Araujo IE. An inter-organ neural circuit for appetite suppression. Cell. 2022;185(14):2478–94.
61. Smith K, Taylor GS, Allerton DM, Brunsgaard LH, Bowden Davies KA, Stevenson EJ, et al. The postprandial glycaemic and hormonal responses following the ingestion of a novel, ready-to-drink shot containing a low dose of whey protein in centrally obese and lean adult males: a randomised controlled trial. Frontiers in Endocrinology. 2021;12:696977.
62. Yu M, Benjamin MM, Srinivasan S, Morin EE, Shishatskaya EI, Schwendeman SP, et al. Battle of GLP-1 delivery technologies. Advanced drug delivery reviews. 2018;130:113–30.
63. Camilleri M, Chedid V, Ford AC, Haruma K, Horowitz M, Jones KL, et al. Gastroparesis. Nature reviews Disease primers. 2018;4(1):41.
64. Halim MA, Degerblad M, Sundbom M, Karlbom U, Holst JJ, Webb D-L, et al. Glucagon-like peptide-1 inhibits prandial gastrointestinal motility through myenteric neuronal mechanisms in humans. The Journal of Clinical Endocrinology & Metabolism. 2018;103(2):575–85.
65. Nauck MA, Quast DR, Wefers J, Pfeiffer AFH. The evolving story of incretins (GIP and GLP‐1) in metabolic and cardiovascular disease: A pathophysiological update. Diabetes, Obesity and Metabolism. 2021;23:5–29.
66. Piper NBC, Whitfield EA, Stewart GD, Xu X, Furness SGB. Targeting appetite and satiety in diabetes and obesity, via G protein-coupled receptors. Biochemical Pharmacology. 2022;202:115115.
67. Andersen ES, Deacon CF, Holst JJ. Do we know the true mechanism of action of the DPP‐4 inhibitors? Diabetes, Obesity and Metabolism. 2018;20(1):34–41.
68. Palha AM, Pereira SS, Costa MM, Morais T, Maia AF, Guimarães M, et al. Differential GIP/GLP‐1 intestinal cell distribution in diabetics’ yields distinctive rearrangements depending on Roux‐en‐Y biliopancreatic limb length. Journal of cellular biochemistry. 2018;119(9):7506–14.
69. Ahn CH, Oh TJ, Kwak SH, Cho YM. Sodium‐glucose cotransporter‐2 inhibition improves incretin sensitivity of pancreatic β‐cells in people with type 2 diabetes. Diabetes, Obesity and Metabolism. 2018;20(2):370–7.
70. Akimoto H, Negishi A, Oshima S, Wakiyama H, Okita M, Horii N, et al. Antidiabetic drugs for the risk of Alzheimer disease in patients with type 2 DM using FAERS. American Journal of Alzheimer’s Disease & Other Dementias®. 2020;35:1533317519899546.
71. Hadamitzky M, Lückemann L, Pacheco-López G, Schedlowski M. Pavlovian conditioning of immunological and neuroendocrine functions. Physiological reviews. 2020;100(1):357–405.
72. McFarland J. Post-Translational Regulation of Glucokinase in Hypothalamic Neurons. University of Maryland, Baltimore; 2020.
73. Fu Z-D, Cai X-L, Yang W-J, Zhao M-M, Li R, Li Y-F. Novel glucose-lowering drugs for non-alcoholic fatty liver disease. World Journal of Diabetes. 2021;12(1):84.
74. Bonnet F, Scheen A. Understanding and overcoming metformin gastrointestinal intolerance. Diabetes, Obesity and Metabolism. 2017;19(4):473–81.
75. Yazbeck R, Jaenisch SE, Abbott CA. Dipeptidyl peptidase 4 inhibitors: Applications in innate immunity? Biochemical Pharmacology. 2021;188:114517.
76. Ramadan WH, Kabbara WK. Sitagliptin/Simvastatin. 2016;
77. Gooßen K, Gräber S. Longer term safety of dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta‐analysis. Diabetes, obesity and metabolism. 2012;14(12):1061–72.
78. Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. Jama. 2019;321(1):69–79.
79. Espeland MA, Pratley RE, Rosenstock J, Kadowaki T, Seino Y, Zinman B, et al. Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase‐4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial. Diabetes, Obesity and Metabolism. 2021;23(2):569–80.
80. Khamdamov BZ, Ganiev AA, Khamdamov IB. The role of cytokines in the immunopatogenesis of acute pancreatitis. Journal of Survey in Fisheries Sciences. 2023;10(2S):3949–58.
81. Muendlein HI, Connolly WM, Cameron J, Jetton D, Magri Z, Smirnova I, et al. Neutrophils and macrophages drive TNF-induced lethality via TRIF/CD14-mediated responses. Science Immunology. 2022;7(78):eadd0665.
82. Mai J, Virtue A, Shen J, Wang H, Yang X-F. An evolving new paradigm: endothelial cells–conditional innate immune cells. Journal of hematology & oncology. 2013;6(1):1–13.
83. Li M, Liu Y, Fu Y, Gong R, Xia H, Huang X, et al. Interleukin-35 inhibits lipopolysaccharide-induced endothelial cell activation by downregulating inflammation and apoptosis. Experimental Cell Research. 2021;407(2):112784.
84. Laird CT, Hassanein W, O’Neill NA, French BM, Cheng X, Fogler WE, et al. P‐and E‐selectin receptor antagonism prevents human leukocyte adhesion to activated porcine endothelial monolayers and attenuates porcine endothelial damage. Xenotransplantation. 2018;25(2):e12381.
85. Argollo M, Gilardi D, Peyrin-Biroulet C, Chabot J-F, Peyrin-Biroulet L, Danese S. Comorbidities in inflammatory bowel disease: a call for action. The Lancet Gastroenterology & Hepatology. 2019;4(8):643–54.
86. Coco C, Sgarra L, Potenza MA, Nacci C, Pasculli B, Barbano R, et al. Can epigenetics of endothelial dysfunction represent the key to precision medicine in type 2 diabetes mellitus? International Journal of Molecular Sciences. 2019;20(12):2949.
87. Ferrari F, Moretti A, Villa RF. Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives. Pharmacology & Therapeutics. 2022;108277.
88. Biessels GJ, Verhagen C, Janssen J, van den Berg E, Wallenstein G, Zinman B, et al. Effects of linagliptin vs glimepiride on cognitive performance in type 2 diabetes: results of the randomised double-blind, active-controlled CAROLINA-COGNITION study. Diabetologia. 2021;64:1235–45.
89. Mok ACH, Mody CH, Li SS. Immune cell degranulation in fungal host defence. Journal of Fungi. 2021;7(6):484.
90. Faint RW. Platelet-neutrophil interaction: neutrophils modulate platelet function. University of London, University College Hospital Medical School (United …; 1992.
91. Breedveld A, Groot Kormelink T, van Egmond M, de Jong EC. Granulocytes as modulators of dendritic cell function. Journal of leukocyte biology. 2017;102(4):1003–16.
92. Mihai MM, Preda M, Lungu I, Gestal MC, Popa MI, Holban AM. Nanocoatings for chronic wound repair—modulation of microbial colonization and biofilm formation. International journal of molecular sciences. 2018;19(4):1179.
93. Roy R, Zayas J, Singh SK, Delgado K, Wood SJ, Mohamed MF, et al. Overriding impaired FPR chemotaxis signaling in diabetic neutrophil stimulates infection control in murine diabetic wound. Elife. 2022;11:e72071.
94. Piipponen M, Li D, Landén NX. The immune functions of keratinocytes in skin wound healing. International journal of molecular sciences. 2020;21(22):8790.
95. Vangaveti VN, Jhamb S, Hayes O, Goodall J, Bulbrook J, Robertson K, et al. Effects of vildagliptin on wound healing and markers of inflammation in patients with type 2 diabetic foot ulcer: a prospective, randomized, double-blind, placebo-controlled, single-center study. Diabetology & Metabolic Syndrome. 2022;14(1):1–8.
96. Li M, Wang Z, Xia H, Yu L, Hu Z. Vildagliptin and G-CSF improved angiogenesis and survival after acute myocardial infarction. Archives of Medical Research. 2019;50(3):133–41.
97. Steven S, Oelze M, Hanf A, Kröller-Schön S, Kashani F, Roohani S, et al. The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats. Redox biology. 2017;13:370–85.
98. Deacon CF, Lebovitz HE. Comparative review of dipeptidyl peptidase‐4 inhibitors and sulphonylureas. Diabetes, Obesity and Metabolism. 2016;18(4):333–47.
99. Ramanathan B. DPP-4 inhibitors in the management of type 2 diabetes mellitus. Progress in Medicine The Association of Physicians of India. 2017;231–7.
100. Segall M, Mansley T, Hunt P, Champness E. Capturing and applying knowledge to guide compound optimisation. Drug discovery today. 2019;24(5):1074–80.
101. Mäder P, Kattner L. Sulfoximines as rising stars in modern drug discovery? Current status and perspective on an emerging functional group in medicinal chemistry. Journal of Medicinal Chemistry. 2020;63(23):14243–75.
102. Hussain H, Abbas G, Green IR, Ali I. Dipeptidyl peptidase IV inhibitors as a potential target for diabetes: patent review (2015-2018). Expert opinion on therapeutic patents. 2019;29(7):535–53.
103. Muskiet MHA, Tonneijck L, Smits MM, Van Baar MJB, Kramer MHH, Hoorn EJ, et al. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nature reviews nephrology. 2017;13(10):605–28.
104. Grosser T, Ricciotti E, FitzGerald GA. The cardiovascular pharmacology of nonsteroidal anti-inflammatory drugs. Trends in pharmacological sciences. 2017;38(8):733–48.
105. Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Vol. 16, Nature Reviews Endocrinology. Nature Research; 2020. p. 642–53.
106. Pasquel FJ, Fayfman M, Umpierrez GE. Debate on insulin vs non-insulin use in the hospital setting—is it time to revise the guidelines for the management of inpatient diabetes? Current diabetes reports. 2019;19:1–11.
107. Van Stee MF, de Graaf AA, Groen AK. Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy. Cardiovascular diabetology. 2018;17(1):1–22.
108. Kahn SE, Chen Y-C, Esser N, Taylor AJ, van Raalte DH, Zraika S, et al. The β cell in diabetes: Integrating biomarkers with functional measures. Endocrine Reviews. 2021;42(5):528–83.
109. Feingold KR, Anawalt B, Boyce A, Chrousos G, Dungan K, Grossman A, et al. Oral and injectable (non-insulin) pharmacological agents for type 2 diabetes. Endotext South Dartmouth (MA). 2020;
110. Mandaliya DK, Seshadri S. Short Chain Fatty Acids, pancreatic dysfunction and type 2 diabetes. Pancreatology. 2019;19(4):617–22.
111. Wang Z, Wang J, Hu J, Chen Y, Dong B, Wang Y. A comparative study of acarbose, vildagliptin and saxagliptin intended for better efficacy and safety on type 2 diabetes mellitus treatment. Life Sciences. 2021;274:119069.
112. Petersen MC, Shulman GI. Roles of diacylglycerols and ceramides in hepatic insulin resistance. Trends in pharmacological sciences. 2017;38(7):649–65.
113. Shao S, Xu Q, Yu X, Pan R, Chen Y. Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions. Pharmacology & therapeutics. 2020;209:107503.
114. Smati S, Canivet CM, Boursier J, Cariou B. Anti-diabetic drugs and NASH: from current options to promising perspectives. Expert opinion on investigational drugs. 2021;30(8):813–25.
115. Shiju R, Akhil A, Thankachan S, Tuomilehto J, Al Arouj M, Bennakhi A. Safety Assessment of Glucose-Lowering Drugs and Importance of Structured Education during Ramadan: A Systematic Review and Meta-Analysis. Journal of diabetes research. 2022;2022.
116. El Ebrashy I, El Kafrawy N, Raouf R, Yousry D. Effectiveness, safety, and tolerability of vildagliptin or vildagliptin/metformin combination in patients with type 2 diabetes uncontrolled on insulin therapy in a real-world setting in Egypt: The OMEGA study. diabetes research and clinical practice. 2020;162:108042.
117. García-Carro C, Vergara A, Agraz I, Jacobs-Cachá C, Espinel E, Seron D, et al. The new era for reno-cardiovascular treatment in type 2 diabetes. Journal of clinical medicine. 2019;8(6):864.
118. Gomez-Peralta F, Abreu C, Gomez-Rodriguez S, Barranco RJ, Umpierrez GE. Safety and efficacy of DPP4 inhibitor and basal insulin in type 2 diabetes: an updated review and challenging clinical scenarios. Diabetes Therapy. 2018;9:1775–89.
119. Matthews DR, Paldánius PM, Proot P, Chiang Y, Stumvoll M, Del Prato S. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. The Lancet. 2019;394(10208):1519–29.
120. Rezki A, Fysekidis M, Chiheb S, Vicaut E, Cosson E, Valensi P. Acute and long-term effects of saxagliptin on post-prandial glycemic response in obese patients with impaired glucose tolerance. Nutrition, Metabolism and Cardiovascular Diseases. 2021;31(4):1257–66.
121. Gallwitz B. Clinical use of DPP-4 inhibitors. Frontiers in endocrinology. 2019;10:389.
122. Kalaitzoglou E, Fowlkes JL, Popescu I, Thrailkill KM. Diabetes pharmacotherapy and effects on the musculoskeletal system. Diabetes/metabolism research and reviews. 2019;35(2):e3100.
123. Chiang C-E, Lin S-Y, Lin T-H, Wang T-D, Yeh H-I, Chen J-F, et al. 2018 consensus of the Taiwan Society of Cardiology and the Diabetes Association of Republic of China (Taiwan) on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases. Journal of the Chinese Medical Association. 2018;81(3):189–222.
124. Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors. Diabetes, Obesity and Metabolism. 2016;18(3):203–16.
125. Skjødt MK, Frost M, Abrahamsen B. Side effects of drugs for osteoporosis and metastatic bone disease. British journal of clinical pharmacology. 2019;85(6):1063–71.
126. Lin S-R, Chang C-H, Tsai M-J, Cheng H, Chen J-C, Leong MK, et al. The perceptions of natural compounds against dipeptidyl peptidase 4 in diabetes: from in silico to in vivo. Therapeutic Advances in Chronic Disease. 2019;10:2040622319875305.
127. Khammissa RAG, Fourie J, Motswaledi MH, Ballyram R, Lemmer J, Feller L. The biological activities of vitamin D and its receptor in relation to calcium and bone homeostasis, cancer, immune and cardiovascular systems, skin biology, and oral health. BioMed research international. 2018;2018.
128. Sagara M, Iijima T, Kase M, Kato K, Sakurai S, Tomaru T, et al. Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis. Journal of Diabetes and its Complications. 2021;35(5):107885.
129. Aird TP, Farquharson AJ, Bermingham KM, O’Sulllivan A, Drew JE, Carson BP. Divergent serum metabolomic, skeletal muscle signaling, transcriptomic, and performance adaptations to fasted versus whey protein-fed sprint interval training. American Journal of Physiology-Endocrinology and Metabolism. 2021;321(6):E802–20.
130. Walsh SW, Al Dulaimi M, Strauss III JF. Aspirin Inhibits the Inflammatory Response of Protease-Activated Receptor 1 in Pregnancy Neutrophils: Implications for Treating Women with Preeclampsia. International Journal of Molecular Sciences. 2022;23(21):13218.
131. Fang L, Ohashi K, Ogawa H, Otaka N, Kawanishi H, Takikawa T, et al. Factor Xa inhibitor, edoxaban ameliorates renal injury after subtotal nephrectomy by reducing epithelial‐mesenchymal transition and inflammatory response. Physiological Reports. 2022;10(5):e15218.
132. Kifle ZD, Woldeyohanin AE, Demeke CA. SARS-CoV-2 and diabetes: A potential therapeutic effect of dipeptidyl peptidase 4 inhibitors in diabetic patients diagnosed with COVID-19. Metabolism Open. 2021;12:100134.
133. Wake D, Cantley P. Davidson’s Self-assessment in Medicine E-Book. Elsevier Health Sciences; 2018.
134. Song B, Shiromoto Y, Minakuchi M, Nishikura K. The role of RNA editing enzyme ADAR1 in human disease. Wiley Interdisciplinary Reviews: RNA. 2022;13(1):e1665.
135. Anderluh M, Kocic G, Tomovic K, Kocic R, Deljanin-Ilic M, Smelcerovic A. Cross-talk between the dipeptidyl peptidase-4 and stromal cell-derived factor-1 in stem cell homing and myocardial repair: potential impact of dipeptidyl peptidase-4 inhibitors. Pharmacology & therapeutics. 2016;167:100–7.
136. Ho TK, Shiwen X, Abraham D, Tsui J, Baker D. Stromal-cell-derived factor-1 (SDF-1)/CXCL12 as potential target of therapeutic angiogenesis in critical leg ischaemia. Cardiology Research and Practice. 2012;2012.
137. Cho EY, Ryu J-Y, Lee HAR, Hong SH, Park HS, Hong KS, et al. Lecithin nano-liposomal particle as a CRISPR/Cas9 complex delivery system for treating type 2 diabetes. Journal of nanobiotechnology. 2019;17:1–12.
138. Kambham N, Higgins JP, Sundram U, Troxell ML. Hematopoietic stem cell transplantation: graft versus host disease and pathology of gastrointestinal tract, liver, and lung. Advances in anatomic pathology. 2014;21(5):301–20.
139. Poncina N. DPP-4 inhibition improves function of endothelial progenitor cells from type 2 diabetic patients. 2015;
140. Asadzadeh Z, Mohammadi H, Safarzadeh E, Hemmatzadeh M, Mahdian-Shakib A, Jadidi-Niaragh F, et al. The paradox of Th17 cell functions in tumor immunity. Cellular Immunology. 2017;322:15–25.
141. Kanasaki K. The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin. Clinical science. 2018;132(4):489–507.
142. Nicotera R, Casarella A, Longhitano E, Bolignano D, Andreucci M, De Sarro G, et al. Antiproteinuric effect of DPP-IV inhibitors in diabetic and non-diabetic kidney diseases. Pharmacological Research. 2020;159:105019.
143. Beck H, Härter M, Haß B, Schmeck C, Baerfacker L. Small molecules and their impact in drug discovery: A perspective on the occasion of the 125th anniversary of the bayer chemical research laboratory. Drug Discovery Today. 2022;
144. Gerry CJ, Schreiber SL. Chemical probes and drug leads from advances in synthetic planning and methodology. Nature Reviews Drug Discovery. 2018;17(5):333–52.
145. Perumal N, Nallappan M, Shohaimi S, Kassim NK, Tee TT, Cheah YH. Synergistic antidiabetic activity of Taraxacum officinale (L.) Weber ex FH Wigg and Momordica charantia L. polyherbal combination. Biomedicine & Pharmacotherapy. 2022;145:112401.
146. Wu L, Zhou M, Xie Y, Lang H, Li T, Yi L, et al. Dihydromyricetin Enhances Exercise-Induced GLP-1 Elevation through Stimulating cAMP and Inhibiting DPP-4. Nutrients. 2022;14(21):4583.
147. Lankatillake C, Huynh T, Dias DA. Understanding glycaemic control and current approaches for screening antidiabetic natural products from evidence-based medicinal plants. Plant Methods. 2019;15(1):1–35.
148. An R, Zhao L, Xi C, Li H, Shen G, Liu H, et al. Melatonin attenuates sepsis-induced cardiac dysfunction via a PI3K/Akt-dependent mechanism. Basic Research in Cardiology. 2016;111:1–15.
149. Wang X. Dipeptidyl peptidase 4 inhibitors and Glucagon-like peptide-1 receptor agonist mitigate inflammation and fibrosis in models of Non-alcoholic steatohepatitis and biliary fibrosis. Dissertation, Mainz, Johannes Gutenberg-Universität, 2016; 2017.
150. Guymer C, Wood JPM, Chidlow G, Casson RJ. Neuroprotection in glaucoma: recent advances and clinical translation. Clinical & experimental ophthalmology. 2019;47(1):88–105.
151. Gupta S, Sen U. More than just an enzyme: Dipeptidyl peptidase-4 (DPP-4) and its association with diabetic kidney remodelling. Pharmacological research. 2019;147:104391.
152. Mahomoodally MF, Lobine D, Picot-Allain MCN, Sadeer N, Jugreet S, Zengin G. Conventional and non-conventional targets of natural products in the management of diabetes mellitus and associated complications. Current Medicinal Chemistry. 2021;28(23):4638–69.
153. Chhabria S, Mathur S, Vadakan S, Sahoo DK, Mishra P, Paital B. A review on phytochemical and pharmacological facets of tropical ethnomedicinal plants as reformed DPP-IV inhibitors to regulate incretin activity. Frontiers in Endocrinology. 2022;13.
154. Mu X, Wang R, Cheng C, Ma Y, Zhang Y, Lu W. Preparation, structural properties, and in vitro and in vivo activities of peptides against dipeptidyl peptidase IV (DPP-IV) and α-glucosidase: a general review. Critical Reviews in Food Science and Nutrition. 2023;1–13.
155. Ayoub BM, Michel HE, Mowaka S, Hendy MS, Tadros MM. Repurposing of omarigliptin as a neuroprotective agent based on docking with A2A adenosine and AChE receptors, brain GLP-1 response and its brain/plasma concentration ratio after 28 days multiple doses in rats using LC-MS/MS. Molecules. 2021;26(4):889.
156. Angelovska B, Drakalska E, Volinkoska J. Knowledge regarding risk factors of hypertension among students in University, Goce Delchev"-Stip. 2017;
157. Ng L, Li H-S, Man AT-K, Chow AK-M, Foo DC-C, Lo OS-H, et al. High Expression of a Cancer Stemness-Related Gene, Chromobox 8 (CBX8), in Normal Tissue Adjacent to the Tumor (NAT) Is Associated with Poor Prognosis of Colorectal Cancer Patients. Cells. 2022;11(11):1852.
158. Chen H-H, Lin C-L, Yeh S-Y, Kao C-H. Short-term dipeptidyl peptidase-4 inhibitor use increases the risk of herpes zoster infection in Asian patients with diabetes. QJM: An International Journal of Medicine. 2015;109(2):91–5.
159. Zommiti M, Feuilloley MGJ, Connil N. Update of probiotics in human world: a nonstop source of benefactions till the end of time. Microorganisms. 2020;8(12):1907.
160. Wang X, Zheng P, Huang G, Yang L, Zhou Z. Dipeptidyl peptidase-4 (DPP-4) inhibitors: promising new agents for autoimmune diabetes. Clinical and experimental medicine. 2018;18:473–80.
161. Gupta R, Srivastava D, Sahu M, Tiwari S, Ambasta RK, Kumar P. Artificial intelligence to deep learning: machine intelligence approach for drug discovery. Molecular diversity. 2021;25:1315–60.
2. Andersen DB, Holst JJ. Peptides in the regulation of glucagon secretion. Peptides. 2022;148:170683.
3. Padhi S, Nayak AK, Behera A. Type II diabetes mellitus: a review on recent drug based therapeutics. Biomedicine & Pharmacotherapy. 2020;131:110708.
4. Deacon CF. Peptide degradation and the role of DPP-4 inhibitors in the treatment of type 2 diabetes. Peptides. 2018;100:150–7.
5. Deacon CF. Metabolism of GIP and the contribution of GIP to the glucose-lowering properties of DPP-4 inhibitors. Peptides. 2020;125:170196.
6. Enz N, Vliegen G, De Meester I, Jungraithmayr W. CD26/DPP4-a potential biomarker and target for cancer therapy. Pharmacology & therapeutics. 2019;198:135–59.
7. Kalaiselvi P. Compare the Safety and Efficacy of Glimepiride–Metformin with Vildagliptin-Metformin in Type 2 Diabetes Mellitus Patients in a Tertiary Care Hospital. Karpaga Vinayaga Institute of Medical Sciences, Madhuranthagam; 2016.
8. Berg M. Design and Synthesis of Novel Drug Candidates for the Treatment of Type 2 Diabetes and Insulin Resistance: Potential SHIP2 Inhibitors. 2021;
9. Mahtani K, MMath BPBs, Wang MAB, Barron A. Activation of GLP-1 receptor signalling by sacubitril/valsartan: Implications for patients with poor glycaemic control. International Journal of Cardiology. 2022;
10. Kumar S, Mittal A, Mittal A. A review upon medicinal perspective and designing rationale of DPP-4 inhibitors. Bioorganic & Medicinal Chemistry. 2021;46:116354.
11. Ghate M, V Jain S. Fragment based HQSAR modeling and docking analysis of conformationally rigid 3-azabicyclo [3.1. 0] hexane derivatives to design selective DPP-4 inhibitors. Letters in Drug Design & Discovery. 2014;11(2):184–98.
12. Adelusi TI, Du L, Chowdhury A, Xiaoke G, Lu Q, Yin X. Signaling pathways and proteins targeted by antidiabetic chalcones. Life Sciences. 2021;284:118982.
13. Diaz DB. Identification of Novel Structural Motifs for Mining the Conformational Space of Boron-and Peptide-based Molecules. University of Toronto (Canada); 2020.
14. Sečník J. Diabetes Mellitus in Patients with Dementia: Clinical Care and Pharmacological Treatment. Karolinska Institutet (Sweden); 2021.
15. Deacon CF. Physiology and pharmacology of DPP-4 in glucose homeostasis and the treatment of type 2 diabetes. Frontiers in endocrinology. 2019;10:80.
16. Tura A, Göbl C, Vardarli I, Pacini G, Nauck M. Insulin clearance and incretin hormones following oral and “isoglycemic” intravenous glucose in type 2 diabetes patients under different antidiabetic treatments. Scientific Reports. 2022;12(1):1–10.
17. Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes, Obesity and Metabolism. 2018;20:5–21.
18. Holst JJ. The incretin system in healthy humans: The role of GIP and GLP-1. Metabolism. 2019;96:46–55.
19. Gasbjerg LS, Bergmann NC, Stensen S, Christensen MB, Rosenkilde MM, Holst JJ, et al. Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists. Peptides. 2020;125:170183.
20. Moffett RC, Naughton V. Emerging role of GIP and related gut hormones in fertility and PCOS. Peptides. 2020;125:170233.
21. Pfeiffer AFH, Keyhani-Nejad F. High glycemic index metabolic damage–a pivotal role of GIP and GLP-1. Trends in Endocrinology & Metabolism. 2018;29(5):289–99.
22. Modvig IM, Kuhre RE, Jepsen SL, Xu SFS, Engelstoft MS, Egerod KL, et al. Amino acids differ in their capacity to stimulate GLP-1 release from the perfused rat small intestine and stimulate secretion by different sensing mechanisms. American Journal of Physiology-Endocrinology and Metabolism. 2021;320(5):E874–85.
23. Mathiesen DS, Bagger JI, Bergmann NC, Lund A, Christensen MB, Vilsbøll T, et al. The effects of dual GLP-1/GIP receptor agonism on glucagon secretion—a review. International journal of molecular sciences. 2019;20(17):4092.
24. Kapodistria K, Tsilibary E, Kotsopoulou E, Moustardas P, Kitsiou P. Liraglutide, a human glucagon‐like peptide‐1 analogue, stimulates AKT‐dependent survival signalling and inhibits pancreatic β‐cell apoptosis. Journal of Cellular and Molecular Medicine. 2018;22(6):2970–80.
25. Hwang H-J, Yang YR, Kim HY, Choi Y, Park K-S, Lee H, et al. Phospholipase C‐β1 potentiates glucose‐stimulated insulin secretion. The FASEB Journal. 2019;33(10):10668–79.
26. Fisman EZ, Tenenbaum A. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: A novel cardiometabolic therapeutic prospect. Cardiovascular Diabetology. 2021;20(1):1–5.
27. Ahren B. DPP-4 inhibitors. Best Practice & Research Clinical Endocrinology & Metabolism. 2007;21(4):517–33.
28. Nauck MA, Wefers J, Meier JJ. Treatment of type 2 diabetes: challenges, hopes, and anticipated successes. The Lancet Diabetes & Endocrinology. 2021;9(8):525–44.
29. Holst JJ. From the incretin concept and the discovery of GLP-1 to today’s diabetes therapy. Frontiers in Endocrinology. 2019;10:260.
30. Samms RJ, Coghlan MP, Sloop KW. How may GIP enhance the therapeutic efficacy of GLP-1? Trends in Endocrinology & Metabolism. 2020;31(6):410–21.
31. Gribble FM, Reimann F. Metabolic messengers: Glucagon-like peptide 1. Nature Metabolism. 2021;3(2):142–8.
32. Codevilla F, Santana E, López AM, Gaidon A. Exploring the limitations of behavior cloning for autonomous driving. In: Proceedings of the IEEE/CVF International Conference on Computer Vision. 2019. p. 9329–38.
33. Tschöp M, Nogueiras R, Ahrén B. Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy. Diabetologia. 2023;1–13.
34. Alsalim W, Persson M, Ahrén B. Different glucagon effects during DPP‐4 inhibition versus SGLT‐2 inhibition in metformin‐treated type 2 diabetes patients. Diabetes, Obesity and Metabolism. 2018;20(7):1652–8.
35. Sebastián-Martín A, Sánchez BG, Mora-Rodríguez JM, Bort A, Díaz-Laviada I. Role of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology. Biomedicines. 2022;10(8):2026.
36. Boer GA, Holst JJ. Incretin hormones and type 2 diabetes—mechanistic insights and therapeutic approaches. Biology. 2020;9(12):473.
37. Sharma A, Virmani T, Sharma A, Chhabra V, Kumar G, Pathak K, et al. Potential Effect of DPP-4 Inhibitors Towards Hepatic Diseases and Associated Glucose Intolerance. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2022;1845–64.
38. Abbatecola AM, Morley JE. Endocrine and Metabolic Changes with Aging. Endocrine and Metabolic Medical Emergencies: A Clinician’s Guide. 2018;182.
39. Holst JJ. Glucagon and other proglucagon-derived peptides in the pathogenesis of obesity. Frontiers in Nutrition. 2022;9.
40. Packer M. Do DPP-4 inhibitors cause heart failure events by promoting adrenergically mediated cardiotoxicity? Clues from laboratory models and clinical trials. Circulation research. 2018;122(7):928–32.
41. Kim H-R, Tagirasa R, Yoo E. Covalent small molecule immunomodulators targeting the protease active site. Journal of Medicinal Chemistry. 2021;64(9):5291–322.
42. Andersen B. DOCTORAL DISSERTATION Translational Aspects of FGF21. 2019;
43. Subrahmanyan NA, Koshy RM, Jacob K, Pappachan JM. Efficacy and cardiovascular safety of DPP-4 inhibitors. Current Drug Safety. 2021;16(2):154–64.
44. Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nature Reviews Endocrinology. 2020;16(11):642–53.
45. Proença C, Ribeiro D, Freitas M, Carvalho F, Fernandes E. A comprehensive review on the antidiabetic activity of flavonoids targeting PTP1B and DPP-4: a structure-activity relationship analysis. Critical reviews in food science and nutrition. 2022;62(15):4095–151.
46. Milluzzo RP, Franchina GA, Capodanno D, Angiolillo DJ. Selatogrel, a novel P2Y12 inhibitor: a review of the pharmacology and clinical development. Expert Opinion on Investigational Drugs. 2020;29(6):537–46.
47. Wu J, Chen Y, Shi X, Gu W. Dipeptidyl peptidase IV (DPP IV): a novel emerging target for the treatment of type 2 diabetes. Journal of Nanjing Medical University. 2009;23(4):228–35.
48. Saini K, Sharma S, Khan Y. DPP-4 inhibitors for treating T2DM-hype or hope? an analysis based on the current literature. Frontiers in Molecular Biosciences. 2023;10.
49. Mikov M, Pavlović N, Stanimirov B, Đanić M, Goločorbin-Kon S, Stankov K, et al. DPP-4 inhibitors: renoprotective potential and pharmacokinetics in type 2 diabetes mellitus patients with renal impairment. European journal of drug metabolism and pharmacokinetics. 2020;45(1):1–14.
50. Iwaniak A, Darewicz M, Minkiewicz P. Peptides derived from foods as supportive diet components in the prevention of metabolic syndrome. Comprehensive Reviews in Food Science and Food Safety. 2018;17(1):63–81.
51. McLean BA, Wong CK, Campbell JE, Hodson DJ, Trapp S, Drucker DJ. Revisiting the complexity of GLP-1 action from sites of synthesis to receptor activation. Endocrine reviews. 2021;42(2):101–32.
52. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes–state-of-the-art. Molecular metabolism. 2021;46:101102.
53. Levi M. Pathogenesis and diagnosis of disseminated intravascular coagulation. International journal of laboratory hematology. 2018;40:15–20.
54. AlRasheid N. Effect of different surgical weight-loss interventions and ethnicity on GLP-1 secretion. UCL (University College London); 2018.
55. Bianchini G, Nigro C, Sirico A, Novelli R, Prevenzano I, Miele C, et al. A new synthetic dual agonist of GPR120/GPR40 induces GLP-1 secretion and improves glucose homeostasis in mice. Biomedicine & Pharmacotherapy. 2021;139:111613.
56. Ren Z-L, Li C-X, Ma C-Y, Chen D, Chen J-H, Xu W-X, et al. Linking Nonalcoholic Fatty Liver Disease and Brain Disease: Focusing on Bile Acid Signaling. International Journal of Molecular Sciences. 2022;23(21):13045.
57. Masi EB, Valdés-Ferrer SI, Steinberg BE. The vagus neurometabolic interface and clinical disease. International journal of obesity. 2018;42(6):1101–11.
58. Hoffman S, Alvares D, Adeli K. GLP-1 attenuates intestinal fat absorption and chylomicron production via vagal afferent nerves originating in the portal vein. Molecular Metabolism. 2022;65:101590.
59. Lim S, Bae JH, Kwon H-S, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nature Reviews Endocrinology. 2021;17(1):11–30.
60. Zhang T, Perkins MH, Chang H, Han W, de Araujo IE. An inter-organ neural circuit for appetite suppression. Cell. 2022;185(14):2478–94.
61. Smith K, Taylor GS, Allerton DM, Brunsgaard LH, Bowden Davies KA, Stevenson EJ, et al. The postprandial glycaemic and hormonal responses following the ingestion of a novel, ready-to-drink shot containing a low dose of whey protein in centrally obese and lean adult males: a randomised controlled trial. Frontiers in Endocrinology. 2021;12:696977.
62. Yu M, Benjamin MM, Srinivasan S, Morin EE, Shishatskaya EI, Schwendeman SP, et al. Battle of GLP-1 delivery technologies. Advanced drug delivery reviews. 2018;130:113–30.
63. Camilleri M, Chedid V, Ford AC, Haruma K, Horowitz M, Jones KL, et al. Gastroparesis. Nature reviews Disease primers. 2018;4(1):41.
64. Halim MA, Degerblad M, Sundbom M, Karlbom U, Holst JJ, Webb D-L, et al. Glucagon-like peptide-1 inhibits prandial gastrointestinal motility through myenteric neuronal mechanisms in humans. The Journal of Clinical Endocrinology & Metabolism. 2018;103(2):575–85.
65. Nauck MA, Quast DR, Wefers J, Pfeiffer AFH. The evolving story of incretins (GIP and GLP‐1) in metabolic and cardiovascular disease: A pathophysiological update. Diabetes, Obesity and Metabolism. 2021;23:5–29.
66. Piper NBC, Whitfield EA, Stewart GD, Xu X, Furness SGB. Targeting appetite and satiety in diabetes and obesity, via G protein-coupled receptors. Biochemical Pharmacology. 2022;202:115115.
67. Andersen ES, Deacon CF, Holst JJ. Do we know the true mechanism of action of the DPP‐4 inhibitors? Diabetes, Obesity and Metabolism. 2018;20(1):34–41.
68. Palha AM, Pereira SS, Costa MM, Morais T, Maia AF, Guimarães M, et al. Differential GIP/GLP‐1 intestinal cell distribution in diabetics’ yields distinctive rearrangements depending on Roux‐en‐Y biliopancreatic limb length. Journal of cellular biochemistry. 2018;119(9):7506–14.
69. Ahn CH, Oh TJ, Kwak SH, Cho YM. Sodium‐glucose cotransporter‐2 inhibition improves incretin sensitivity of pancreatic β‐cells in people with type 2 diabetes. Diabetes, Obesity and Metabolism. 2018;20(2):370–7.
70. Akimoto H, Negishi A, Oshima S, Wakiyama H, Okita M, Horii N, et al. Antidiabetic drugs for the risk of Alzheimer disease in patients with type 2 DM using FAERS. American Journal of Alzheimer’s Disease & Other Dementias®. 2020;35:1533317519899546.
71. Hadamitzky M, Lückemann L, Pacheco-López G, Schedlowski M. Pavlovian conditioning of immunological and neuroendocrine functions. Physiological reviews. 2020;100(1):357–405.
72. McFarland J. Post-Translational Regulation of Glucokinase in Hypothalamic Neurons. University of Maryland, Baltimore; 2020.
73. Fu Z-D, Cai X-L, Yang W-J, Zhao M-M, Li R, Li Y-F. Novel glucose-lowering drugs for non-alcoholic fatty liver disease. World Journal of Diabetes. 2021;12(1):84.
74. Bonnet F, Scheen A. Understanding and overcoming metformin gastrointestinal intolerance. Diabetes, Obesity and Metabolism. 2017;19(4):473–81.
75. Yazbeck R, Jaenisch SE, Abbott CA. Dipeptidyl peptidase 4 inhibitors: Applications in innate immunity? Biochemical Pharmacology. 2021;188:114517.
76. Ramadan WH, Kabbara WK. Sitagliptin/Simvastatin. 2016;
77. Gooßen K, Gräber S. Longer term safety of dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta‐analysis. Diabetes, obesity and metabolism. 2012;14(12):1061–72.
78. Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. Jama. 2019;321(1):69–79.
79. Espeland MA, Pratley RE, Rosenstock J, Kadowaki T, Seino Y, Zinman B, et al. Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase‐4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial. Diabetes, Obesity and Metabolism. 2021;23(2):569–80.
80. Khamdamov BZ, Ganiev AA, Khamdamov IB. The role of cytokines in the immunopatogenesis of acute pancreatitis. Journal of Survey in Fisheries Sciences. 2023;10(2S):3949–58.
81. Muendlein HI, Connolly WM, Cameron J, Jetton D, Magri Z, Smirnova I, et al. Neutrophils and macrophages drive TNF-induced lethality via TRIF/CD14-mediated responses. Science Immunology. 2022;7(78):eadd0665.
82. Mai J, Virtue A, Shen J, Wang H, Yang X-F. An evolving new paradigm: endothelial cells–conditional innate immune cells. Journal of hematology & oncology. 2013;6(1):1–13.
83. Li M, Liu Y, Fu Y, Gong R, Xia H, Huang X, et al. Interleukin-35 inhibits lipopolysaccharide-induced endothelial cell activation by downregulating inflammation and apoptosis. Experimental Cell Research. 2021;407(2):112784.
84. Laird CT, Hassanein W, O’Neill NA, French BM, Cheng X, Fogler WE, et al. P‐and E‐selectin receptor antagonism prevents human leukocyte adhesion to activated porcine endothelial monolayers and attenuates porcine endothelial damage. Xenotransplantation. 2018;25(2):e12381.
85. Argollo M, Gilardi D, Peyrin-Biroulet C, Chabot J-F, Peyrin-Biroulet L, Danese S. Comorbidities in inflammatory bowel disease: a call for action. The Lancet Gastroenterology & Hepatology. 2019;4(8):643–54.
86. Coco C, Sgarra L, Potenza MA, Nacci C, Pasculli B, Barbano R, et al. Can epigenetics of endothelial dysfunction represent the key to precision medicine in type 2 diabetes mellitus? International Journal of Molecular Sciences. 2019;20(12):2949.
87. Ferrari F, Moretti A, Villa RF. Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives. Pharmacology & Therapeutics. 2022;108277.
88. Biessels GJ, Verhagen C, Janssen J, van den Berg E, Wallenstein G, Zinman B, et al. Effects of linagliptin vs glimepiride on cognitive performance in type 2 diabetes: results of the randomised double-blind, active-controlled CAROLINA-COGNITION study. Diabetologia. 2021;64:1235–45.
89. Mok ACH, Mody CH, Li SS. Immune cell degranulation in fungal host defence. Journal of Fungi. 2021;7(6):484.
90. Faint RW. Platelet-neutrophil interaction: neutrophils modulate platelet function. University of London, University College Hospital Medical School (United …; 1992.
91. Breedveld A, Groot Kormelink T, van Egmond M, de Jong EC. Granulocytes as modulators of dendritic cell function. Journal of leukocyte biology. 2017;102(4):1003–16.
92. Mihai MM, Preda M, Lungu I, Gestal MC, Popa MI, Holban AM. Nanocoatings for chronic wound repair—modulation of microbial colonization and biofilm formation. International journal of molecular sciences. 2018;19(4):1179.
93. Roy R, Zayas J, Singh SK, Delgado K, Wood SJ, Mohamed MF, et al. Overriding impaired FPR chemotaxis signaling in diabetic neutrophil stimulates infection control in murine diabetic wound. Elife. 2022;11:e72071.
94. Piipponen M, Li D, Landén NX. The immune functions of keratinocytes in skin wound healing. International journal of molecular sciences. 2020;21(22):8790.
95. Vangaveti VN, Jhamb S, Hayes O, Goodall J, Bulbrook J, Robertson K, et al. Effects of vildagliptin on wound healing and markers of inflammation in patients with type 2 diabetic foot ulcer: a prospective, randomized, double-blind, placebo-controlled, single-center study. Diabetology & Metabolic Syndrome. 2022;14(1):1–8.
96. Li M, Wang Z, Xia H, Yu L, Hu Z. Vildagliptin and G-CSF improved angiogenesis and survival after acute myocardial infarction. Archives of Medical Research. 2019;50(3):133–41.
97. Steven S, Oelze M, Hanf A, Kröller-Schön S, Kashani F, Roohani S, et al. The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats. Redox biology. 2017;13:370–85.
98. Deacon CF, Lebovitz HE. Comparative review of dipeptidyl peptidase‐4 inhibitors and sulphonylureas. Diabetes, Obesity and Metabolism. 2016;18(4):333–47.
99. Ramanathan B. DPP-4 inhibitors in the management of type 2 diabetes mellitus. Progress in Medicine The Association of Physicians of India. 2017;231–7.
100. Segall M, Mansley T, Hunt P, Champness E. Capturing and applying knowledge to guide compound optimisation. Drug discovery today. 2019;24(5):1074–80.
101. Mäder P, Kattner L. Sulfoximines as rising stars in modern drug discovery? Current status and perspective on an emerging functional group in medicinal chemistry. Journal of Medicinal Chemistry. 2020;63(23):14243–75.
102. Hussain H, Abbas G, Green IR, Ali I. Dipeptidyl peptidase IV inhibitors as a potential target for diabetes: patent review (2015-2018). Expert opinion on therapeutic patents. 2019;29(7):535–53.
103. Muskiet MHA, Tonneijck L, Smits MM, Van Baar MJB, Kramer MHH, Hoorn EJ, et al. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nature reviews nephrology. 2017;13(10):605–28.
104. Grosser T, Ricciotti E, FitzGerald GA. The cardiovascular pharmacology of nonsteroidal anti-inflammatory drugs. Trends in pharmacological sciences. 2017;38(8):733–48.
105. Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Vol. 16, Nature Reviews Endocrinology. Nature Research; 2020. p. 642–53.
106. Pasquel FJ, Fayfman M, Umpierrez GE. Debate on insulin vs non-insulin use in the hospital setting—is it time to revise the guidelines for the management of inpatient diabetes? Current diabetes reports. 2019;19:1–11.
107. Van Stee MF, de Graaf AA, Groen AK. Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy. Cardiovascular diabetology. 2018;17(1):1–22.
108. Kahn SE, Chen Y-C, Esser N, Taylor AJ, van Raalte DH, Zraika S, et al. The β cell in diabetes: Integrating biomarkers with functional measures. Endocrine Reviews. 2021;42(5):528–83.
109. Feingold KR, Anawalt B, Boyce A, Chrousos G, Dungan K, Grossman A, et al. Oral and injectable (non-insulin) pharmacological agents for type 2 diabetes. Endotext South Dartmouth (MA). 2020;
110. Mandaliya DK, Seshadri S. Short Chain Fatty Acids, pancreatic dysfunction and type 2 diabetes. Pancreatology. 2019;19(4):617–22.
111. Wang Z, Wang J, Hu J, Chen Y, Dong B, Wang Y. A comparative study of acarbose, vildagliptin and saxagliptin intended for better efficacy and safety on type 2 diabetes mellitus treatment. Life Sciences. 2021;274:119069.
112. Petersen MC, Shulman GI. Roles of diacylglycerols and ceramides in hepatic insulin resistance. Trends in pharmacological sciences. 2017;38(7):649–65.
113. Shao S, Xu Q, Yu X, Pan R, Chen Y. Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions. Pharmacology & therapeutics. 2020;209:107503.
114. Smati S, Canivet CM, Boursier J, Cariou B. Anti-diabetic drugs and NASH: from current options to promising perspectives. Expert opinion on investigational drugs. 2021;30(8):813–25.
115. Shiju R, Akhil A, Thankachan S, Tuomilehto J, Al Arouj M, Bennakhi A. Safety Assessment of Glucose-Lowering Drugs and Importance of Structured Education during Ramadan: A Systematic Review and Meta-Analysis. Journal of diabetes research. 2022;2022.
116. El Ebrashy I, El Kafrawy N, Raouf R, Yousry D. Effectiveness, safety, and tolerability of vildagliptin or vildagliptin/metformin combination in patients with type 2 diabetes uncontrolled on insulin therapy in a real-world setting in Egypt: The OMEGA study. diabetes research and clinical practice. 2020;162:108042.
117. García-Carro C, Vergara A, Agraz I, Jacobs-Cachá C, Espinel E, Seron D, et al. The new era for reno-cardiovascular treatment in type 2 diabetes. Journal of clinical medicine. 2019;8(6):864.
118. Gomez-Peralta F, Abreu C, Gomez-Rodriguez S, Barranco RJ, Umpierrez GE. Safety and efficacy of DPP4 inhibitor and basal insulin in type 2 diabetes: an updated review and challenging clinical scenarios. Diabetes Therapy. 2018;9:1775–89.
119. Matthews DR, Paldánius PM, Proot P, Chiang Y, Stumvoll M, Del Prato S. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. The Lancet. 2019;394(10208):1519–29.
120. Rezki A, Fysekidis M, Chiheb S, Vicaut E, Cosson E, Valensi P. Acute and long-term effects of saxagliptin on post-prandial glycemic response in obese patients with impaired glucose tolerance. Nutrition, Metabolism and Cardiovascular Diseases. 2021;31(4):1257–66.
121. Gallwitz B. Clinical use of DPP-4 inhibitors. Frontiers in endocrinology. 2019;10:389.
122. Kalaitzoglou E, Fowlkes JL, Popescu I, Thrailkill KM. Diabetes pharmacotherapy and effects on the musculoskeletal system. Diabetes/metabolism research and reviews. 2019;35(2):e3100.
123. Chiang C-E, Lin S-Y, Lin T-H, Wang T-D, Yeh H-I, Chen J-F, et al. 2018 consensus of the Taiwan Society of Cardiology and the Diabetes Association of Republic of China (Taiwan) on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases. Journal of the Chinese Medical Association. 2018;81(3):189–222.
124. Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors. Diabetes, Obesity and Metabolism. 2016;18(3):203–16.
125. Skjødt MK, Frost M, Abrahamsen B. Side effects of drugs for osteoporosis and metastatic bone disease. British journal of clinical pharmacology. 2019;85(6):1063–71.
126. Lin S-R, Chang C-H, Tsai M-J, Cheng H, Chen J-C, Leong MK, et al. The perceptions of natural compounds against dipeptidyl peptidase 4 in diabetes: from in silico to in vivo. Therapeutic Advances in Chronic Disease. 2019;10:2040622319875305.
127. Khammissa RAG, Fourie J, Motswaledi MH, Ballyram R, Lemmer J, Feller L. The biological activities of vitamin D and its receptor in relation to calcium and bone homeostasis, cancer, immune and cardiovascular systems, skin biology, and oral health. BioMed research international. 2018;2018.
128. Sagara M, Iijima T, Kase M, Kato K, Sakurai S, Tomaru T, et al. Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis. Journal of Diabetes and its Complications. 2021;35(5):107885.
129. Aird TP, Farquharson AJ, Bermingham KM, O’Sulllivan A, Drew JE, Carson BP. Divergent serum metabolomic, skeletal muscle signaling, transcriptomic, and performance adaptations to fasted versus whey protein-fed sprint interval training. American Journal of Physiology-Endocrinology and Metabolism. 2021;321(6):E802–20.
130. Walsh SW, Al Dulaimi M, Strauss III JF. Aspirin Inhibits the Inflammatory Response of Protease-Activated Receptor 1 in Pregnancy Neutrophils: Implications for Treating Women with Preeclampsia. International Journal of Molecular Sciences. 2022;23(21):13218.
131. Fang L, Ohashi K, Ogawa H, Otaka N, Kawanishi H, Takikawa T, et al. Factor Xa inhibitor, edoxaban ameliorates renal injury after subtotal nephrectomy by reducing epithelial‐mesenchymal transition and inflammatory response. Physiological Reports. 2022;10(5):e15218.
132. Kifle ZD, Woldeyohanin AE, Demeke CA. SARS-CoV-2 and diabetes: A potential therapeutic effect of dipeptidyl peptidase 4 inhibitors in diabetic patients diagnosed with COVID-19. Metabolism Open. 2021;12:100134.
133. Wake D, Cantley P. Davidson’s Self-assessment in Medicine E-Book. Elsevier Health Sciences; 2018.
134. Song B, Shiromoto Y, Minakuchi M, Nishikura K. The role of RNA editing enzyme ADAR1 in human disease. Wiley Interdisciplinary Reviews: RNA. 2022;13(1):e1665.
135. Anderluh M, Kocic G, Tomovic K, Kocic R, Deljanin-Ilic M, Smelcerovic A. Cross-talk between the dipeptidyl peptidase-4 and stromal cell-derived factor-1 in stem cell homing and myocardial repair: potential impact of dipeptidyl peptidase-4 inhibitors. Pharmacology & therapeutics. 2016;167:100–7.
136. Ho TK, Shiwen X, Abraham D, Tsui J, Baker D. Stromal-cell-derived factor-1 (SDF-1)/CXCL12 as potential target of therapeutic angiogenesis in critical leg ischaemia. Cardiology Research and Practice. 2012;2012.
137. Cho EY, Ryu J-Y, Lee HAR, Hong SH, Park HS, Hong KS, et al. Lecithin nano-liposomal particle as a CRISPR/Cas9 complex delivery system for treating type 2 diabetes. Journal of nanobiotechnology. 2019;17:1–12.
138. Kambham N, Higgins JP, Sundram U, Troxell ML. Hematopoietic stem cell transplantation: graft versus host disease and pathology of gastrointestinal tract, liver, and lung. Advances in anatomic pathology. 2014;21(5):301–20.
139. Poncina N. DPP-4 inhibition improves function of endothelial progenitor cells from type 2 diabetic patients. 2015;
140. Asadzadeh Z, Mohammadi H, Safarzadeh E, Hemmatzadeh M, Mahdian-Shakib A, Jadidi-Niaragh F, et al. The paradox of Th17 cell functions in tumor immunity. Cellular Immunology. 2017;322:15–25.
141. Kanasaki K. The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin. Clinical science. 2018;132(4):489–507.
142. Nicotera R, Casarella A, Longhitano E, Bolignano D, Andreucci M, De Sarro G, et al. Antiproteinuric effect of DPP-IV inhibitors in diabetic and non-diabetic kidney diseases. Pharmacological Research. 2020;159:105019.
143. Beck H, Härter M, Haß B, Schmeck C, Baerfacker L. Small molecules and their impact in drug discovery: A perspective on the occasion of the 125th anniversary of the bayer chemical research laboratory. Drug Discovery Today. 2022;
144. Gerry CJ, Schreiber SL. Chemical probes and drug leads from advances in synthetic planning and methodology. Nature Reviews Drug Discovery. 2018;17(5):333–52.
145. Perumal N, Nallappan M, Shohaimi S, Kassim NK, Tee TT, Cheah YH. Synergistic antidiabetic activity of Taraxacum officinale (L.) Weber ex FH Wigg and Momordica charantia L. polyherbal combination. Biomedicine & Pharmacotherapy. 2022;145:112401.
146. Wu L, Zhou M, Xie Y, Lang H, Li T, Yi L, et al. Dihydromyricetin Enhances Exercise-Induced GLP-1 Elevation through Stimulating cAMP and Inhibiting DPP-4. Nutrients. 2022;14(21):4583.
147. Lankatillake C, Huynh T, Dias DA. Understanding glycaemic control and current approaches for screening antidiabetic natural products from evidence-based medicinal plants. Plant Methods. 2019;15(1):1–35.
148. An R, Zhao L, Xi C, Li H, Shen G, Liu H, et al. Melatonin attenuates sepsis-induced cardiac dysfunction via a PI3K/Akt-dependent mechanism. Basic Research in Cardiology. 2016;111:1–15.
149. Wang X. Dipeptidyl peptidase 4 inhibitors and Glucagon-like peptide-1 receptor agonist mitigate inflammation and fibrosis in models of Non-alcoholic steatohepatitis and biliary fibrosis. Dissertation, Mainz, Johannes Gutenberg-Universität, 2016; 2017.
150. Guymer C, Wood JPM, Chidlow G, Casson RJ. Neuroprotection in glaucoma: recent advances and clinical translation. Clinical & experimental ophthalmology. 2019;47(1):88–105.
151. Gupta S, Sen U. More than just an enzyme: Dipeptidyl peptidase-4 (DPP-4) and its association with diabetic kidney remodelling. Pharmacological research. 2019;147:104391.
152. Mahomoodally MF, Lobine D, Picot-Allain MCN, Sadeer N, Jugreet S, Zengin G. Conventional and non-conventional targets of natural products in the management of diabetes mellitus and associated complications. Current Medicinal Chemistry. 2021;28(23):4638–69.
153. Chhabria S, Mathur S, Vadakan S, Sahoo DK, Mishra P, Paital B. A review on phytochemical and pharmacological facets of tropical ethnomedicinal plants as reformed DPP-IV inhibitors to regulate incretin activity. Frontiers in Endocrinology. 2022;13.
154. Mu X, Wang R, Cheng C, Ma Y, Zhang Y, Lu W. Preparation, structural properties, and in vitro and in vivo activities of peptides against dipeptidyl peptidase IV (DPP-IV) and α-glucosidase: a general review. Critical Reviews in Food Science and Nutrition. 2023;1–13.
155. Ayoub BM, Michel HE, Mowaka S, Hendy MS, Tadros MM. Repurposing of omarigliptin as a neuroprotective agent based on docking with A2A adenosine and AChE receptors, brain GLP-1 response and its brain/plasma concentration ratio after 28 days multiple doses in rats using LC-MS/MS. Molecules. 2021;26(4):889.
156. Angelovska B, Drakalska E, Volinkoska J. Knowledge regarding risk factors of hypertension among students in University, Goce Delchev"-Stip. 2017;
157. Ng L, Li H-S, Man AT-K, Chow AK-M, Foo DC-C, Lo OS-H, et al. High Expression of a Cancer Stemness-Related Gene, Chromobox 8 (CBX8), in Normal Tissue Adjacent to the Tumor (NAT) Is Associated with Poor Prognosis of Colorectal Cancer Patients. Cells. 2022;11(11):1852.
158. Chen H-H, Lin C-L, Yeh S-Y, Kao C-H. Short-term dipeptidyl peptidase-4 inhibitor use increases the risk of herpes zoster infection in Asian patients with diabetes. QJM: An International Journal of Medicine. 2015;109(2):91–5.
159. Zommiti M, Feuilloley MGJ, Connil N. Update of probiotics in human world: a nonstop source of benefactions till the end of time. Microorganisms. 2020;8(12):1907.
160. Wang X, Zheng P, Huang G, Yang L, Zhou Z. Dipeptidyl peptidase-4 (DPP-4) inhibitors: promising new agents for autoimmune diabetes. Clinical and experimental medicine. 2018;18:473–80.
161. Gupta R, Srivastava D, Sahu M, Tiwari S, Ambasta RK, Kumar P. Artificial intelligence to deep learning: machine intelligence approach for drug discovery. Molecular diversity. 2021;25:1315–60.
Article Sidebar
Published
Nov 18, 2022
Article Details
How to Cite
Parul Srivastava, Pranay Wal, Versha Chaturvedi, Ankita Wal, & Ashish Srivastava. (2022). BEYOND BLOOD SUGAR CONTROL: A COMPREHENSIVE REVIEW OF DPP-4 INHIBITORS AND THEIR EXPANDING LANDSCAPE. Journal of Population Therapeutics and Clinical Pharmacology, 29(04), 1273–1303. https://doi.org/10.53555/jptcp.v29i04.4372
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Author Biographies
Parul Srivastava
PSIT- Pranveer Singh Institute of Technology, (Pharmacy), Kanpur-209305, Uttar Pradesh, India.
Pranay Wal
PSIT- Pranveer Singh Institute of Technology, (Pharmacy), Kanpur-209305, Uttar Pradesh, India.
Versha Chaturvedi
PSIT- Pranveer Singh Institute of Technology, (Pharmacy), Kanpur-209305, Uttar Pradesh, India.
Ankita Wal
PSIT- Pranveer Singh Institute of Technology, (Pharmacy), Kanpur-209305, Uttar Pradesh, India.
Ashish Srivastava
PSIT- Pranveer Singh Institute of Technology, (Pharmacy), Kanpur-209305, Uttar Pradesh, India.